OPTN - OptiNose, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

OptiNose, Inc.

1020 Stony Hill Road
Suite 300
Yardley, PA 19067
United States
267-364-3500
http://www.optinose.com

SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees102

Key Executives

NameTitlePayExercisedYear Born
Mr. Peter K. MillerCEO & Director778.6kN/A1961
Dr. Ramy A. Mahmoud M.D., M.P.H.Pres & COO609kN/A1965
Mr. Keith Alan GoldanChief Financial Officer486.67kN/A1971
Mr. Michael F. MarinoChief Legal Officer & Corp. Sec.510.5kN/A1976
Ms. Ricci WhitlowSr. VP of Technical & Corp. OperationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder. It has a license agreement with Inexia Limited to manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.

Corporate Governance

OptiNose, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.